




LUNG CANCER **UPDATES**

ASCO HIGHLIGHTS

31 MAYO - 4 JUNIO 2019



Con la colaboración de:



Bristol-Myers Squibb

illumina

Lilly



ASCO HIGHLIGHTS

31 MAYO - 4 JUNIO 2019



CPNM con mutación EGFR

Dr. Bartomeu Massutí

Día 3

Con la colaboración de:



Bristol-Myers Squibb


illumina

Lilly

Combinación EGFR-TKI + Antiangiogénico

EC REPLAY

- EC Fase III
- Objetivo primario: PFS evaluada por investigador
- HR 0.71 / 270 eventos
- Objetivos secundarios: OS, RR, DCR, DoR
- Pre-especificados PFS2 y biomarcadores
- En-16-Feb-18
- 449 p
- 100 centros
- En el momento del análisis continúan en tratamiento 19% control vs 29% exper.



RELAY: Baseline Characteristics

n (%)		RAM+ERL (N=224)	PBO+ERL (N=225)
Sex	Female	141 (63)	142 (63)
Age	Median (Min-Max), years	65 (27-86)	64 (23-89)
Race ^a	Asian	172 (77)	174 (77)
	Caucasian	52 (23)	48 (21)
Smoking history	Never	134 (60)	139 (62)
ECOG performance status	0	116 (52)	119 (53)
Disease classification	Primary metastatic	195 (87)	191 (85)
	Recurrent metastatic	29 (13)	34 (15)
EGFR mutation type ^b	Exon 19 deletion	123 (55)	121 (54)
	Exon 21 (L858R) mutation	101 (45)	104 (46)
EGFR testing method ^b	therascreen® and cobas®	96 (43)	101 (45)
	Other ^c	127 (57)	124 (55)

^aPBO+ERL arm included 3 Other: 1 American Indian or Alaska Native, 1 Black or African American, and 1 Missing


^bDetermined by local testing; ^cPCR and sequencing-based methods

PRESENTED AT: 2019 ASCO ANNUAL MEETING | #ASCO19 | Prof. Kazuhiko Nakagawa, MD, PhD | Kindai University Faculty of Medicine, Osaka, Japan

Combinación EGFR-TKI + Antiangiogénico

EC REPLAY

RELAY Primary Endpoint: PFS (Investigator-Assessed)



	RAM+ERL n=224	PBO+ERL n=225
Events	122	158
Median, mo (95% CI)	19.4 (15.4–21.6)	12.4 (11.0–13.5)
HR (95% CI)	0.591 (0.461, 0.760)	
P-value	<0.0001	


Patients at Risk:

RAM+ERL 224	196	170	154	133	103	69	49	32	20	10	1	0
PBO+ERL 225	196	167	136	99	72	52	37	27	15	4	4	0

Consistent PFS benefit by independent, blinded central review (HR 0.671, 95% CI 0.518 – 0.869; p=0.0022)

	RAM+ERL N=224	PBO+ERL N=225
ORR % (95% CI)	76 (71–82)	75 (69–80)
DCR % (95% CI)	95 (92–98)	96 (93–98)
Duration of Response	N=171	N=168
Events	101 (59)	128 (76)
Median, mo (95% CI)	18.0 (13.9–19.8)	11.1 (9.7–12.3)
HR (95% CI)	0.619 (0.477, 0.805)	

Duration of response





- HR 0.65 Del19
- HR 0.62 L858R

- No difs:
 - Tasa de Respuesta
 - Tasa de control enf.

Combinación EGFR-TKI + Antiangiogénico

EC REPLAY



- EAs > G3:
- 72% vs 54%
- No difs. discontinuación tto.
- Aumento diarrea, rash e hipertensión arterial



Combinación EGFR-TKI + QT

Gefitinib vs Gefitinib + Carbo-Pem


- Objetivo primario PFS
- Hipótesis: PFS de 10 a 15 m
712 p valorados
- 350 p aleatorizados
- EAs G $\geq$ 3: 50.65% vs 25.3%
- PFS G $\rightarrow$ 8 m
- PFS G+Cb+P $\rightarrow$ 16 m
- HR 0.51 (p<0.001)



Subgroup	Gefitinib + Pembicicarb/ Carboplatin arm Events(n)/Patients(N)	Gefitinib arm Events(n)/Patients(N)	Hazard Ratio (95% CI)
Age of screening			
$\leq$ 60 years	73/131	99/119	0.45 (0.33-0.61)
$>$ 60 years	26/43	38/57	0.65 (0.39-1.08)
Sex			
Male	55/88	73/93	0.59 (0.42-0.84)
Female	44/86	65/83	0.43 (0.29-0.64)
Exon Mutation at randomization			
Exon-19	58/109	86/110	0.49 (0.35-0.69)
Others	41/65	52/66	0.53 (0.35-0.8)
Brain metastases			
Present	19/39	27/34	0.53 (0.29-0.98)
Absent	80/144	111/142	0.51 (0.38-0.68)
ECOG Performance Status			
0-1	75/138	106/137	0.48 (0.36-0.65)
2	24/36	32/39	0.57 (0.33-0.98)
Overall	99/174	138/176	0.51 (0.39-0.66)

How to Integrate the Results of RELAY and Chemo + Gefitinib Trial in the Current Landscape of *EGFR* Mutant Treatment?

- In the perspective of the whole treatment sequence



TAK-788 en inserciones Exon 20

- 28 p tratados con 160 mg/24 h
- (6 escalada dosis + 22 cohorte expansión)
- Pretratados (mediana líneas tto. 3)
- 79% tto. previo anti-EGFR
- 43% metas SNC
- Mediana tiempo en tratamiento 7.9 m
- Tasa respuesta 43% / DCR 86%
- mPFS 7.3 m
- 63% EAs G3

